Phase 3 Hypertension Trial, Recruiting (NCT05625724)

Phase 3 Hypertension Trial, Recruiting NCT05625724 Sponsor: University Hospital, Toulouse Condition: Hypertension

Printed from Voxsanity (voxsanity.com.au) — NCT05625724 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Hypertension

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are a woman aged 18 or older who has never given birth before
You became pregnant through assisted reproduction techniques, such as IVF, ICSI, egg donation, or donor sperm insemination
You are carrying a single baby (not twins or more)
Your pregnancy is progressing normally and you are between 9 and 14 weeks pregnant
You are covered by French Social Security or an equivalent social protection scheme
You are willing and able to give written consent to participate

Who may not be able to join:

Your baby has been found to have a serious abnormality
You are already taking aspirin regularly, including if you have a condition called antiphospholipid syndrome
You cannot take aspirin due to an allergy, a bleeding disorder (such as von Willebrand disease or hemophilia), stomach ulcers, or another medical reason
You are in a legally protected category that restricts participation in research (confirm with trial site)
You are already taking part in another clinical trial that involves a treatment or intervention

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 2 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05625724

Sponsor: University Hospital, Toulouse

Phase: Phase 3

Status: Recruiting

Condition: Hypertension

More information: https://clinicaltrials.gov/study/NCT05625724

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are a woman aged 18 or older who has never given birth before
You became pregnant through assisted reproduction techniques, such as IVF, ICSI, egg donation, or donor sperm insemination
You are carrying a single baby (not twins or more)
Your pregnancy is progressing normally and you are between 9 and 14 weeks pregnant
You are covered by French Social Security or an equivalent social protection scheme
You are willing and able to give written consent to participate

Who may not be able to join:

Your baby has been found to have a serious abnormality
You are already taking aspirin regularly, including if you have a condition called antiphospholipid syndrome
You cannot take aspirin due to an allergy, a bleeding disorder (such as von Willebrand disease or hemophilia), stomach ulcers, or another medical reason
You are in a legally protected category that restricts participation in research (confirm with trial site)
You are already taking part in another clinical trial that involves a treatment or intervention

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 2 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

University Hospital, Toulouse

Registry

ClinicalTrials.gov

Start date

2 August 2023

Est. completion

1 August 2028

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Effect of aspirin 150mg daily initiated between 9 and 14 weeks of gestation versus placebo in the prevention of preterm (<37 weeks of gestation) preeclampsia

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov